EP0208764A1 - Method for preserving liposomes - Google Patents

Method for preserving liposomes

Info

Publication number
EP0208764A1
EP0208764A1 EP86900891A EP86900891A EP0208764A1 EP 0208764 A1 EP0208764 A1 EP 0208764A1 EP 86900891 A EP86900891 A EP 86900891A EP 86900891 A EP86900891 A EP 86900891A EP 0208764 A1 EP0208764 A1 EP 0208764A1
Authority
EP
European Patent Office
Prior art keywords
liposomes
trehalose
preserving
initial
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86900891A
Other languages
German (de)
French (fr)
Other versions
EP0208764A4 (en
Inventor
John H. Crowe
Lois M. Crowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP0208764A1 publication Critical patent/EP0208764A1/en
Publication of EP0208764A4 publication Critical patent/EP0208764A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric

Definitions

  • the present invention relates generally to liposomes, and more particularly relates to a method of preserving liposomes containing biologically active mol ⁇ ecules. This process is useful in applications such as in vivo drug delivery and preservation of diagnostic agents.
  • Liposomes are unilamellar or multila ⁇ iellar lipid vesicles which enclose a fluid space.
  • the walls of the vesicles are formed by a bimolecular layer of one or more lipid components having polar heads and non-polar tails.
  • the polar heads of one layer orient outwardly to extend into the surrounding medium, and the non-polar tail portions of the lipids associate with each other, thus providing a polar surface and a non-polar core in the wall of the vesicle.
  • Unilamellar liposomes have one such bimolecu ⁇ lar layer, whereas multilamellar liposomes generally have a plurality of substantially concentric bimolecular layers.
  • Liposomes are well recognized as useful for encapsulation of drugs and other therapeutic agents and for carrying these agents to in vivo sites. For example.
  • U.S. Patent 3,993,754 inventors Rahman et al., issued November 23, 1976, discloses an improved chemotherapy method in which an anti-tumor drug is encapsulated within liposomes and then injected.
  • Liposomes have also been used successfully for introducing various chemicals, biochemicals, genetic material and the like into viable cells _ir ⁇ vitro, and as carriers for diagnostic agents.
  • a preserving agent such as trehalose
  • a method for preserving liposomes includes freeze-drying liposomes in the presence"of a preserving agent capable of preserving structure and function in biological mem ⁇ branes.
  • Preferred preserving agents include carbohy ⁇ drates having at least two monosaccharide units, and especially preferred compounds include the disaccharides sucrose, maltose, and trehalose.
  • the method comprises freeze-drying liposomes which in addi ⁇ tion to containing biologically active molecules or therapeutic agents contain a preserving agent such as trehalose internally.
  • a preserving agent such as trehalose internally.
  • an appropriate compound such as trehal ⁇ ose is present both inside and outside the lipid membrane; preferred weight ratios of total preserving agent to lipid range from about 0.1:1 to 3.0:1. An especially preferred weight ratio is about 1.0:1.0.
  • the invention also embodies a lyophilized composition such that when reconstituted by rehydration, resultant liposomes retain substantially all of their originally encapsulated material.
  • a lyophilized composition may be prepared by the method as outlined above.
  • the invention comprises a method for preserving liposomes containing biologically active molecules using a preserving agent.
  • the method involves either freeze- drying liposomes in the presence of a preserving agent, or freeze-drying liposomes which contain a preserving agent internally in addition to encapsulated medicaments, or both.
  • Preferred preserving agents are carbohydrates having at least two monosaccharide units joined in glycosidic linkage, and particularly preferred pre ⁇ serving agents include sucrose, maltose and trehalose. Of these, trehalose has been found to be the most effective preserving agent for use with the inventive method.
  • Trehalose is a naturally occurring sugar found at high concentrations in organisms capable of surviving dehydration. Trehalose is especially effective in pre ⁇ serving structure and function in dry biological mem ⁇ branes. Liposomes which are freeze-dried in the presence of trehalose and which additionally contain encapsulated trehalose, exhibit particularly good retention of encap ⁇ sulates. That is, when liposomes are exposed to tre ⁇ halose both internally and externally during freeze- drying, they can retain as much as 100% of their original encapsulated contents upon rehydration. This is in sharp contrast to liposomes which are freeze-dried without any preserving agent, which show extensive fusion between liposomes and loss of contents to the surrounding medium.
  • Representative phospholipids used in forming liposomes which may be used in this process include phos- phatidylcholine, phosphatidylserine, phosphatidic acid and mixtures thereof. Both natural and synthetic phos ⁇ pholipids may be successfully used.
  • the biologically active or therapeutic encap ⁇ sulated material is preferably water soluble.
  • suitable therapeutic agents include sympathomimetic drugs such as amphetamine sulfate, epi- nephrine hy ⁇ rochloride, or ephedrine hydrochloride; an- tispasmodics such as atropine or scopalamine; broncho- dilators such as isoproternol; vasodilators such as dilthiazen; hormones such as insulin; and antineoplastic drugs such as adria ycin.
  • Suitable biologically active molecules include, for example, RNA, DNA, enzymes and immunoglobulins.
  • Small unilamellar vesicles are pre ⁇ pared as starting materials prior to encapsulation of trehalose, and may be prepared by any of the available techniques. Suitable techniques include injection of the lipid in an organic solvent into water, extrusion from a French pressure cell, and sonication.
  • the material to be trapped may be added at any stage during preparation of the small unilamellar vesicles, but in practice it is most convenient to mix the small unilamellar vesicles with an aqueous solution of the material to be trapped immedi ⁇ ately before preparation of large unilamellar vesicles.
  • Preferred weight ratios of encapsulate to lipid are about 1.0:1.0.
  • LUV's Large unilamellar vesicles with in ⁇ creased trapping efficiency may then be prepared by either freeze-thawing or rotary evaporation.
  • An exemplary rotary evaporation method and one which is especially effective in conjunction with the method disclosed herein is illustrated in Deamer, D. ., "A Novel Method for Encapsulation of Macromolecules in Liposomes" in Gregori- adis, G. (ed.) Liposome Technology (1984).
  • the method comprises providing a polar solution having initial liposomes and a quantity of material to be encapsulated. Substantially all of the solution is removed, and the resultant liposomes are then recovered by hydration of the concentrated admixture.
  • Trehalose may be added at any stage during preparation of the large unilamellar vesicles, but greatly improved preservation is attained with trehalose present on both sides of the phospholipid bilayer. Therefore, trehalose is preferably added before the large
  • unilamellar vesicles are prepared, so that trehalose is trapped inside.
  • the preferred weight ratio of total trehalose to lipid ranges from about 0.1:1 to about 3.0:1; a particularly preferred weight ratio is approximately 1.0:1.0.
  • the large unilamellar vesicles are then frozen in liquid nitrogen and lyophilized. Under some circum ⁇ stances, as when lipids are used which are susceptible to damage due to the presence of oxygen, it may be desirable to seal the dry preparations under vacuum. Rehydration is accomplished simply by adding water to the dry mixture.
  • the liposomes are exposed to trehalose
  • preserving agents including carbohydrate compounds which are composed of at least two monosac ⁇ charide units.
  • sucrose and maltose are suitable alternatives.
  • Example 1 A phopholipid mixture consisting of approximately 40 mg. dipalmitoyl phosphatidylcholine and phosphatidic acid in a molar ratio of 95:5 was sonicated to optical clarity in a bath sonicator. Large unilamellar vesicles were prepared by freeze-thawing in a 50 mM solution of isocitric acid in water as the compound to be encap ⁇ sulated. Excess isocitric acid was removed by dialysis.
  • Trehalose 2.0:1.0 trehalose:phospholipid weight ratio
  • Isocitric acid was assayed by adding isocitrate dehydrogenase and NADP to the outside of the vesicles according to the method of Plaut, et al. (Eds.), Methods in Enzy ology, Volume 5 (New York: Aca ⁇ demic Press).
  • Isocitrate external to the vesicles was oxidized by the isocitrate dehydrogenase, resulting in reduction of NADP to NADPH, the rate and amount of which may be recorded fluorometrically.
  • Total isocitric acid in the vesicles was assayed following addition of Triton X-100 (octylphenoxy polyethoxyethanol, a detergent and emulsifier manufactured by Rohm & Haas Co., Philadelphia, PA; "TRITON” is a registered trademark of Rohm & Haas Co.), which releases the trapped isocitric acid into the surrounding medium.
  • Triton X-100 octylphenoxy polyethoxyethanol, a detergent and emulsifier manufactured by Rohm & Haas Co., Philadelphia, PA; "TRITON” is a registered trademark of Rohm & Haas Co.
  • Example 2 Small unilamellar vesicles of were made by sonication of 43 mg egg phosphatidylcholine in 4 ml of water. Large unilamellar vesicles were prepared by rotary drying the phospholipid in the presence of 32 mg of trehalose and 13 mg of isocitric acid. The weight ratios of phospholipid:trehalose:isocitric acid were approxi ⁇ mately 4:3:1. Excess isocitric acid and trehalose were removed by dialysis against distilled water, and the amount of isocitric acid trapped in the vesicles was determined by the enzyme assay described in Example 1.
  • Trehalose was added to the dialyzed liposomes to give a final weight ratio of phospholipid:trehalose of 1.0:1.4, and the sample was lyophilized. The sample was then rehydrated with distilled water, and the amount of isocitric acid remaining in the liposomes was determined by enzyme assay. The lyophilized vesicles retained 75% of their original contents.
  • Example 3 A phospholipid mixture of palmitoyloleoyl phosphatidylcholine (90%) and phosphatidylserine (10%) was hydrated to 10 mg./ l., and small unilamellar vesicles were then prepared by sonication. Large uni ⁇ lamellar vesicles were prepared by rotary drying in the presence of isocitric acid, which served as the encap ⁇ sulated molecule. Essentially the same techniques as previously described in Examples 1 and 2 were used. Efficiency of retention of isocitric acid following lyophilization and rehydration was recorded as before, with large unilamellar vesicles lyophilized first in the presence and then in the absence of trehalose. As may be seen in Table 2, the results show that 100% of the trapped
  • isocitric acid is retained when the large unilamellar vesicles are lyophilized and rehydrated under the stated conditions.
  • tre ⁇ halose is preferably present both externally and inter ⁇ nally to optimize retention of the encapsulate.
  • Example 4 One of the damaging events presumed to be occurring during lyophilization is close approach of the large unilamellar vesicles to each other, leading to fusion and leakage of the vesicular contents. Fusion has been assayed by resonance energy transfer, a fluorescence method which depends upon energy transfer from an excited probe (the "donor probe") to a second probe (the “acceptor probe”). The acceptor probe fluoresces when the energy transfer occurs. In order for the transfer to occur the two probes must be in close proximity. Thus probe intermixing can be used as an assay for fusion between vesicles during lyophilization.
  • Example 5 A further experiment was carried out identical to that set forth in Example 3, with first maltose and then sucrose as the preserving agent. Results are set forth in Tables 4 and 5. As may be concluded from those tables, both maltose and sucrose provide good retention of encapsulated material following lyophilization.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nouveau procédé de conservation de liposomes contenant des molécules biologiquement actives, tel que les structures des liposomes, une fois réhydratées, conservent pratiquement toutes les substances initialement encapsulées. Un agent de conservation possédant au moins deux éléments de monosaccharide est utilisé soit de manière interne soit de manière externe ou les deux. Dans un mode préférentiel de réalisation, on utilise comme agent de conservation du tréhalose, à la fois à l'intérieur des liposomes sous forme d'une substance encapsulée et de manière externe, en solution, pendant la lyophilisation. L'invention concerne également une composition lyophilisée préparée à l'aide du procédé ci-décrit.New method for preserving liposomes containing biologically active molecules, such that the structures of liposomes, once rehydrated, conserve practically all the substances initially encapsulated. A preservative having at least two elements of monosaccharide is used either internally or externally or both. In a preferred embodiment, trehalose is used as a preservative, both inside the liposomes in the form of an encapsulated substance and externally, in solution, during lyophilization. The invention also relates to a lyophilized composition prepared using the process described below.

Description

METHOD FOR PRESERVING LIPOSOMES
Field of the Invention
The present invention relates generally to liposomes, and more particularly relates to a method of preserving liposomes containing biologically active mol¬ ecules. This process is useful in applications such as in vivo drug delivery and preservation of diagnostic agents.
This invention was made with Government support under Grant No. PCM 82-17538 with the National Science Foundation and the University of California. The Govern¬ ment has certain rights in this invention.
Background of the Invention
Liposomes are unilamellar or multilaπiellar lipid vesicles which enclose a fluid space. The walls of the vesicles are formed by a bimolecular layer of one or more lipid components having polar heads and non-polar tails. In an aqueous (or polar) solution, the polar heads of one layer orient outwardly to extend into the surrounding medium, and the non-polar tail portions of the lipids associate with each other, thus providing a polar surface and a non-polar core in the wall of the vesicle. Unilamellar liposomes have one such bimolecu¬ lar layer, whereas multilamellar liposomes generally have a plurality of substantially concentric bimolecular layers.
Liposomes are well recognized as useful for encapsulation of drugs and other therapeutic agents and for carrying these agents to in vivo sites. For example.
U.S. Patent 3,993,754, inventors Rahman et al., issued November 23, 1976, discloses an improved chemotherapy method in which an anti-tumor drug is encapsulated within liposomes and then injected. U.S. Patent 4,263,428, inventors Apple et al., issued April 21, 1981, discloses an antitumor drug which may be more effectively delivered to selective cell sites in a mammalian organism by incorporating the drug within uniformly sized liposomes. Drug administration via liposomes can have reduced toxicity, altered tissue distribution, increased drug effectiveness, and an improved therapeutic index.
Liposomes have also been used successfully for introducing various chemicals, biochemicals, genetic material and the like into viable cells _irι vitro, and as carriers for diagnostic agents.
A variety" of methods for' preparing liposomes are known, many of which have been described by Szoka and Papahadjopoulos, Ann-. Rev. Biophysics Bioeng. 9: 467-508 (1980). Also, several liposome encapsulation methods are disclosed in the patent literature, notably in U.S. patent 4,235,871, to Papahadjopoulos et al., issued November 25, 1980, and in U.S. patent 4,U16,100 to Suzuki et al., issued April 5, 1977.
Although encapsulation of therapeutic agents and biologically active compounds in liposomes has sig¬ nificant commercial potential, a major difficulty that has been encountered in the commercial use of liposome encapsulates is with their long term stability. Although liposome structures may be maintained intact under certain storage conditions, such conditions are often inconvenient or unavailable. It is as a solution to this problem that the method of this invention is presented.
Summary of the Invention
Accordingly, it is an object of the present invention to provide a commercially feasible method of preserving liposomes.
It is another object of the present invention to provide a commercially feasible method of preserving liposomes by means of freeze-drying, wherein upon rehy- dration, resultant liposomes can retain as much as 100% of their original encapsulated material.
It is still another object of the present invention to provide a method of preserving liposomes by means of a carbohydrate compound capable of preserving structure and function in biological membranes.
It is a further object of the present invention to provide a method of preserving liposomes by means of a preserving agent such as trehalose, present either as encapsulated material inside the 'liposome or externally in solution during freeze-drying, or both.
It is yet another object of the present invention to provide a lyophilized composition which upon rehydration retains up to 100% of original encapsulated material.
Further objects and advantages of this inven¬ tion will become apparent from the study of the following portion of the specification, the claims and the attached drawings.
In one aspect of the present invention, a method for preserving liposomes includes freeze-drying liposomes in the presence"of a preserving agent capable of preserving structure and function in biological mem¬ branes. Preferred preserving agents include carbohy¬ drates having at least two monosaccharide units, and especially preferred compounds include the disaccharides sucrose, maltose, and trehalose.
In another aspect of the present invention, the method comprises freeze-drying liposomes which in addi¬ tion to containing biologically active molecules or therapeutic agents contain a preserving agent such as trehalose internally. In a preferred embodiment of the inventive method, an appropriate compound such as trehal¬ ose is present both inside and outside the lipid membrane; preferred weight ratios of total preserving agent to lipid range from about 0.1:1 to 3.0:1. An especially preferred weight ratio is about 1.0:1.0.
The invention also embodies a lyophilized composition such that when reconstituted by rehydration, resultant liposomes retain substantially all of their originally encapsulated material. Such a lyophilized composition may be prepared by the method as outlined above.
Detailed Description of the Invention
The invention comprises a method for preserving liposomes containing biologically active molecules using a preserving agent. The method involves either freeze- drying liposomes in the presence of a preserving agent, or freeze-drying liposomes which contain a preserving agent internally in addition to encapsulated medicaments, or both. Preferred preserving agents are carbohydrates having at least two monosaccharide units joined in glycosidic linkage, and particularly preferred pre¬ serving agents include sucrose, maltose and trehalose. Of these, trehalose has been found to be the most effective preserving agent for use with the inventive method.
Trehalose is a naturally occurring sugar found at high concentrations in organisms capable of surviving dehydration. Trehalose is especially effective in pre¬ serving structure and function in dry biological mem¬ branes. Liposomes which are freeze-dried in the presence of trehalose and which additionally contain encapsulated trehalose, exhibit particularly good retention of encap¬ sulates. That is, when liposomes are exposed to tre¬ halose both internally and externally during freeze- drying, they can retain as much as 100% of their original encapsulated contents upon rehydration. This is in sharp contrast to liposomes which are freeze-dried without any preserving agent, which show extensive fusion between liposomes and loss of contents to the surrounding medium.
Representative phospholipids used in forming liposomes which may be used in this process include phos- phatidylcholine, phosphatidylserine, phosphatidic acid and mixtures thereof. Both natural and synthetic phos¬ pholipids may be successfully used.
The biologically active or therapeutic encap¬ sulated material is preferably water soluble. Examples of suitable therapeutic agents with which this preserva¬ tion method can successfully be carried out include sympathomimetic drugs such as amphetamine sulfate, epi- nephrine hyάrochloride, or ephedrine hydrochloride; an- tispasmodics such as atropine or scopalamine; broncho- dilators such as isoproternol; vasodilators such as dilthiazen; hormones such as insulin; and antineoplastic drugs such as adria ycin. Suitable biologically active molecules include, for example, RNA, DNA, enzymes and immunoglobulins.
Small unilamellar vesicles (SUV's) are pre¬ pared as starting materials prior to encapsulation of trehalose, and may be prepared by any of the available techniques. Suitable techniques include injection of the lipid in an organic solvent into water, extrusion from a French pressure cell, and sonication. The material to be trapped may be added at any stage during preparation of the small unilamellar vesicles, but in practice it is most convenient to mix the small unilamellar vesicles with an aqueous solution of the material to be trapped immedi¬ ately before preparation of large unilamellar vesicles. Preferred weight ratios of encapsulate to lipid are about 1.0:1.0.
Large unilamellar vesicles (LUV's) with in¬ creased trapping efficiency may then be prepared by either freeze-thawing or rotary evaporation. An exemplary rotary evaporation method and one which is especially effective in conjunction with the method disclosed herein is illustrated in Deamer, D. ., "A Novel Method for Encapsulation of Macromolecules in Liposomes" in Gregori- adis, G. (ed.) Liposome Technology (1984). The method comprises providing a polar solution having initial liposomes and a quantity of material to be encapsulated. Substantially all of the solution is removed, and the resultant liposomes are then recovered by hydration of the concentrated admixture. This method is also the subject of pending U.S. Patent Application Serial No. 493,952, inventor Deamer, et al., filed May 12, 1983. The resulting vesicles may then be made more uniform by filtration, centrifugation or gel permeation chromato- graphy.
Trehalose may be added at any stage during preparation of the large unilamellar vesicles, but greatly improved preservation is attained with trehalose present on both sides of the phospholipid bilayer. Therefore, trehalose is preferably added before the large
unilamellar vesicles are prepared, so that trehalose is trapped inside. The preferred weight ratio of total trehalose to lipid ranges from about 0.1:1 to about 3.0:1; a particularly preferred weight ratio is approximately 1.0:1.0. The large unilamellar vesicles are then frozen in liquid nitrogen and lyophilized. Under some circum¬ stances, as when lipids are used which are susceptible to damage due to the presence of oxygen, it may be desirable to seal the dry preparations under vacuum. Rehydration is accomplished simply by adding water to the dry mixture.
Although in a preferred embodiment of the invention, the liposomes are exposed to trehalose, it should be understood that a variety of preserving agents may be substituted for trehalose, including carbohydrate compounds which are composed of at least two monosac¬ charide units. In particular, sucrose and maltose are suitable alternatives.
The following examples illustrate certain as¬ pects and embodiments of the present invention, and are not intended to limit the scope of the invention as defined in the appended claims.
Example 1 A phopholipid mixture consisting of approximately 40 mg. dipalmitoyl phosphatidylcholine and phosphatidic acid in a molar ratio of 95:5 was sonicated to optical clarity in a bath sonicator. Large unilamellar vesicles were prepared by freeze-thawing in a 50 mM solution of isocitric acid in water as the compound to be encap¬ sulated. Excess isocitric acid was removed by dialysis. Trehalose (2.0:1.0 trehalose:phospholipid weight ratio) was added either after freeze-thawing or beforehand, thus providing some large unilamellar vesicles with external trehalose only and some vesicles with trehalose both externally and internally. Isocitric acid was assayed by adding isocitrate dehydrogenase and NADP to the outside of the vesicles according to the method of Plaut, et al. (Eds.), Methods in Enzy ology, Volume 5 (New York: Aca¬ demic Press). Isocitrate external to the vesicles was oxidized by the isocitrate dehydrogenase, resulting in reduction of NADP to NADPH, the rate and amount of which may be recorded fluorometrically. Total isocitric acid in the vesicles was assayed following addition of Triton X-100 (octylphenoxy polyethoxyethanol, a detergent and emulsifier manufactured by Rohm & Haas Co., Philadelphia, PA; "TRITON" is a registered trademark of Rohm & Haas Co.), which releases the trapped isocitric acid into the surrounding medium. Isocitric acid trapped in the vesi¬ cles was assayed before and after both lyophilization and rehydration, thus providing an estimate of the efficiency with which the trapped isocitrate was retained. As may be seen in Table 1, the results show that over sixty percent (60%) of the trapped isocitrate was retained when the vesicles were lyophilized with trehalose both inside and outside the vesicles. When trehalose was present externally only, there was still a significant increase in the efficiency of retention, but to a lesser degree than in the case where trehalose was present on both sides of the lipid membrane. Examination of lipid concen¬ tration at time of freezing showed that such had no significant effect on retention of trapped material following lyophilization. Table 1
Method of
Preparing Concentration g Trehalose Trehalose %Reten- LUV ' s of Lipid /g Lipid External Internal tion
(mg/ml)
FT* 10.8 0 0
FT 11.1 0.08 0
FT 10.8 1.78 + 42
FT 11.1 1.78 + 61
rFT = freeze-thaw
10
Example 2 Small unilamellar vesicles of were made by sonication of 43 mg egg phosphatidylcholine in 4 ml of water. Large unilamellar vesicles were prepared by rotary drying the phospholipid in the presence of 32 mg of trehalose and 13 mg of isocitric acid. The weight ratios of phospholipid:trehalose:isocitric acid were approxi¬ mately 4:3:1. Excess isocitric acid and trehalose were removed by dialysis against distilled water, and the amount of isocitric acid trapped in the vesicles was determined by the enzyme assay described in Example 1. Trehalose was added to the dialyzed liposomes to give a final weight ratio of phospholipid:trehalose of 1.0:1.4, and the sample was lyophilized. The sample was then rehydrated with distilled water, and the amount of isocitric acid remaining in the liposomes was determined by enzyme assay. The lyophilized vesicles retained 75% of their original contents.
Example 3 A phospholipid mixture of palmitoyloleoyl phosphatidylcholine (90%) and phosphatidylserine (10%) was hydrated to 10 mg./ l., and small unilamellar vesicles were then prepared by sonication. Large uni¬ lamellar vesicles were prepared by rotary drying in the presence of isocitric acid, which served as the encap¬ sulated molecule. Essentially the same techniques as previously described in Examples 1 and 2 were used. Efficiency of retention of isocitric acid following lyophilization and rehydration was recorded as before, with large unilamellar vesicles lyophilized first in the presence and then in the absence of trehalose. As may be seen in Table 2, the results show that 100% of the trapped
11
isocitric acid is retained when the large unilamellar vesicles are lyophilized and rehydrated under the stated conditions. As the previous examples demonstrated, tre¬ halose is preferably present both externally and inter¬ nally to optimize retention of the encapsulate.
Example 4 One of the damaging events presumed to be occurring during lyophilization is close approach of the large unilamellar vesicles to each other, leading to fusion and leakage of the vesicular contents. Fusion has been assayed by resonance energy transfer, a fluorescence method which depends upon energy transfer from an excited probe (the "donor probe") to a second probe (the "acceptor probe"). The acceptor probe fluoresces when the energy transfer occurs. In order for the transfer to occur the two probes must be in close proximity. Thus probe intermixing can be used as an assay for fusion between vesicles during lyophilization. Large unilamellar vesi¬ cles were prepared with donor probe in one preparation and acceptor probe in another, and the two preparations were mixed before lyophilization. Following lyophilization and rehydration, probe intermixing was measured, with the results listed in Table 3. The results show that with increasing trehalose concentration there is a decrease in probe intermixing. Furthermore, the presence of tre¬ halose inside the liposomes alone significantly reduce probe mixing. Thus, use of trehalose tends to reduce fusion of the vesicles.
12
Table 2
Method of
Preparing g Trehalose Trehalose %Reten-
LUV's /q Lipid External Internal tion
RD* 0.06 + 0
RD 3.2 + + 100
RD 0 - - 0
RD 3.9 + - 26
RD 0.11 + + 22
RD 0.19 + + 49
RD 0.33 + + 69
RD 0.63 + + 76
RD 0.91* + + 86
RD 1.76 + + 99
*RD = rotary drying
13
Table 3
Method of
Preparing g Trehalose Trehalose % Probe
LUV's JS Lipid External Internal Mixing
RD* 0.05 + 72
RD 0.15 + + 39
RD 0.25 + + 29
RD 0.50 + + 12
RD 0.95 + + 8
FT** 0. - - 93.0
FT 0.4 + + 79.0
FT 0.8 + + 59.0
FT 1.2 . + + 54.0
FT 1.6 + + 38.0
FT 2.0 + + 15.0
*RD = rotary drying **FT = freeze-thaw
FUSION BETWEEN PALMITOYLOLEOYL PHOSPHATIDYLCHOLINE: PHOSPHATIDYLSERINE (90:10) LARGE UNILAMELLAR VESICLES, AS ASSAYED BY RESONANCE ENERGY TRANSFER BETWEEN FLUORES¬ CENT PROBES 14
Example 5 A further experiment was carried out identical to that set forth in Example 3, with first maltose and then sucrose as the preserving agent. Results are set forth in Tables 4 and 5. As may be concluded from those tables, both maltose and sucrose provide good retention of encapsulated material following lyophilization.
Table 4
Method of
Preparing g Trehalose Trehalose %Reten-
LUV's JSL Lipid External Internal tion
RD 0.05 + 3
RD 0.15 + + 41
RD 0.25 + + 88
RD 0.49 + + 95
RD 0.64 + + 100
Table 5
Method of
Preparing g Trehalose Trehalose %Reten-
LUV's /g Lipid External Internal tion
RD 0.07 + 20
RD 0.35 + + 57
RD 0.49 + + 89
RD 0.83 + + 86
RD 1.15 + + 91

Claims

15Claims
1. A method for preserving liposomes, com¬ prising: providing initial liposomes, said liposomes having an initial quantity of water-soluble material encapsulated therein, said material including a first preserving agent; contacting said initial liposomes with a second preserving agent in an aqueous solution; and, lyophilizing said initial liposomes in the presence of said second preserving agent to form lyo¬ philizates.
2. The method as in claim 1, further com¬ prising recovering resultant liposomes from said lyo¬ philizates by admixing said lyophilizates with an aqueous solution, wherein the resultant liposomes encapsulate at least about 25 wt.% of said initial quantity of encap¬ sulated material.
3. The method as in claim 2, wherein said first preserving agent is trehalose, and said resultant liposomes encapsulate at least about 60% of said initial quantity of encapsulated material.
4. The method as in claim 1 or 2, wherein the weight ratio of said first and second preserving agents, combined, to lipid, ranges from about 0.1:1 to about 3.0:1.
5. The method as in claim 4, wherein said weight ratio is approximately 1.0:1.0.
16
6. The method as in claim 1 or 2, wherein said first preserving agent comprises at least two mono¬ saccharide units.
7. The method as in claim 6, wherein said first preserving agent is selected from the group consisting of trehalose, maltose and sucrose.
8. The method as in claim 1 or 2, wherein said second preserving agent comprises at least two mono¬ saccharide units.
9. The method as in claim 8, wherein said second preserving agent is selected from the group consisting of trehalose, maltose and sucrose.
10. A lyophilized composition useful in storing encapsulated material, prepared by the process comprising: providing initial liposomes, said liposomes having an initial quantity of material encapsulated therein, said material including a quantity of trehalose; contacting said initial liposomes with a quan¬ tity of trehalose in aqueous solution; lyophilizing said initial liposomes in the presence of trehalose to form lyophilizates.
11. The composition of claim 10, wherein said encapsulated material includes a water-soluble thera¬ peutic agent or biologically active compound. 17
12. The composition of claim 11, wherein said encapsulated material includes a macromolecule.
13. The composition of claim 12, wherein said encapsulated material includes a sympathomimetic drug, an antispasmodic, a vasodilator, an antineoplastic drug, RNA, DNA, an enzyme, or an immunoglobulin.
EP19860900891 1985-01-11 1986-01-08 Method for preserving liposomes. Withdrawn EP0208764A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69067985A 1985-01-11 1985-01-11
US690679 1985-01-11

Publications (2)

Publication Number Publication Date
EP0208764A1 true EP0208764A1 (en) 1987-01-21
EP0208764A4 EP0208764A4 (en) 1987-10-08

Family

ID=24773483

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860900891 Withdrawn EP0208764A4 (en) 1985-01-11 1986-01-08 Method for preserving liposomes.

Country Status (6)

Country Link
EP (1) EP0208764A4 (en)
JP (1) JPS62501631A (en)
AU (1) AU587600B2 (en)
CA (1) CA1275248C (en)
DK (1) DK175799B1 (en)
WO (1) WO1986003938A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5484432A (en) * 1985-09-27 1996-01-16 Laser Biotech, Inc. Collagen treatment apparatus
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
WO1988006441A1 (en) * 1987-02-23 1988-09-07 Vestar, Inc. Dehydrating vesicule preparations for long-term storage
ATE107502T1 (en) * 1988-10-05 1994-07-15 Vestar Inc METHOD OF PREPARING LIPOSOMES WITH IMPROVED STABILITY DURING DRYING.
US6007817A (en) 1988-10-11 1999-12-28 University Of Southern California Vasopermeability enhancing immunoconjugates
IL91933A (en) * 1988-10-11 1994-12-29 Univ Southern California Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
DE69233119T2 (en) * 1991-06-18 2004-05-13 Imarx Pharmaceutical Corp., Tucson NEW LIPOSOMAL DRUG RELEASE SYSTEMS
JP3187622B2 (en) 1993-10-07 2001-07-11 カネボウ株式会社 Liposome
AU2215995A (en) * 1994-04-07 1995-10-30 Akzo Nobel N.V. Freeze-dried compositions comprising rna
DK0967862T3 (en) * 1997-02-07 2003-05-12 Elan Drug Delivery Ltd Methods and compositions for preparing dried, storage-stable platelets
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US6710038B1 (en) 1999-12-14 2004-03-23 Kibun Food Chemifa Co., Ltd. Emulsification method using propylene glycol hyaluronate
EP1255439A4 (en) 2000-02-10 2007-01-03 Univ California Therapeutic platelets and methods
US6770478B2 (en) 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
PL363618A1 (en) * 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
WO2005002546A1 (en) * 2003-06-27 2005-01-13 Smithkline Beecham Corporation Stabilized topotecan liposomal composition and methods
JPWO2008026310A1 (en) * 2006-08-29 2010-01-14 株式会社セレックス Trehalose-containing oral mucosa protective agent
ES2657686T3 (en) 2009-06-24 2018-03-06 Lipoid Gmbh Composition for cosmetic, pharmaceutical or dietary applications
SI2768484T1 (en) 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Lyophilized liposomes
US10448631B2 (en) 2015-09-22 2019-10-22 East Carolina University Cryopreservation using sucralose
EP3813788A1 (en) 2018-06-27 2021-05-05 Breath Therapeutics GmbH Pharmaceutical compositions in lyophilized form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2002319A (en) * 1977-08-05 1979-02-21 Battelle Memorial Institute Process for the dehydration of a colloidal dispersion of liposomes
WO1985004326A1 (en) * 1984-03-23 1985-10-10 Biocompatibles Ltd. Polymeric liposomes as stable gas carriers
WO1986001103A1 (en) * 1984-08-08 1986-02-27 The Liposome Company, Inc. Dehydrated liposomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2002319A (en) * 1977-08-05 1979-02-21 Battelle Memorial Institute Process for the dehydration of a colloidal dispersion of liposomes
WO1985004326A1 (en) * 1984-03-23 1985-10-10 Biocompatibles Ltd. Polymeric liposomes as stable gas carriers
WO1986001103A1 (en) * 1984-08-08 1986-02-27 The Liposome Company, Inc. Dehydrated liposomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8603938A1 *

Also Published As

Publication number Publication date
JPS62501631A (en) 1987-07-02
AU5318386A (en) 1986-07-29
DK428386A (en) 1986-11-11
AU587600B2 (en) 1989-08-24
DK175799B1 (en) 2005-02-28
CA1275248C (en) 1990-10-16
DK428386D0 (en) 1986-09-08
EP0208764A4 (en) 1987-10-08
WO1986003938A1 (en) 1986-07-17

Similar Documents

Publication Publication Date Title
AU587600B2 (en) Method for preserving liposomes
KR920002300B1 (en) Method for preserving liposomes
US4857319A (en) Method for preserving liposomes
JP2574999B2 (en) Dehydrated liposome pharmaceutical preparation
US4931361A (en) Cryoprotective reagents in freeze-drying membranes
EP0437479B1 (en) Method of making liposomes with improved stability during drying
US4235871A (en) Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en) Method of encapsulating biologically active materials in lipid vesicles
EP0354855B1 (en) Liposomes on which adsorption of proteins is inhibited
AU741784B2 (en) Modulation of drug loading in multivesicular liposomes
US6355267B1 (en) Liposome preparation and material encapsulation method
US4900556A (en) System for delayed and pulsed release of biologically active substances
CA2181390C (en) Phospholipid formulations
JPH01502590A (en) Liposomes with long circulation time
JPH06104622B2 (en) Method for manufacturing liposomal formulation
AU721085B2 (en) Improved liposomal formulation
AU625857B2 (en) Gelcores
CA2048471C (en) Water-containing liposome system
Wasankar et al. Liposome as a drug delivery system-a review
EP0393145A1 (en) Spontaneous vesiculation of multilamellar liposomes
AU646520B2 (en) Phospholipid analogue vesicle with a succinimidyl moiety
Kim et al. Effect of bovine serum albumin on the stability of methotrexate-encapsulated liposomes
AU616040B2 (en) Agents for inhibiting adsorption of proteins on the liposome surface
Gregory Preparation of Liposomes and Oily Formulations by Freeze-Drying of Monophase Solutions
CA1329548C (en) Liposomal preparation and antibiotic

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19861001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19871008

17Q First examination report despatched

Effective date: 19900202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930212

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CROWE, JOHN, H.

Inventor name: CROWE, LOIS, M.